Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Gerhartz

Showing results (91-100 of 118) with videos related to

Pageof 12
Sort By:
Leukemia Research|February 1, 1993
Intervention treatment of established neutropenia with human recombinant granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in patients undergoing cancer chemotherapyH H Gerhartz, A C Stern, B Wolf-Hornung, et al.
Onkologie|February 1, 1988
[Multicenter prospective risk-adapted study on the therapy of non-Hodgkin's lymphomas of high malignancy. Use of COP-BLAM/IMVP-16 and randomized adjuvant radiotherapy--study concept and preliminary results]W Siegert, D Huhn, A Neubauer, et al.
Medical Oncology and Tumor Pharmacotherapy|January 1, 1989
Chemotherapy of Hodgkin's lymphoma with alternating cycles of COPP (cyclophosphamide, vincristin, procarbazine, prednisone) and ABVD (doxorubicin, bleomycin, vinblastine and dacarbazine). Results of the HD1 and HD3 trials of the German Hodgkin Study GroupV Diehl, M Pfreundschuh, M Löffler, et al.
Bone Marrow Transplantation|December 1, 1989
Low-dose Ara-C plus granulocyte/macrophage colony-stimulating factor for the treatment of myelodysplastic syndromes. EORTC Leukemia GroupH H Gerhartz, G Visani, A Delmer, et al.
Onkologie|February 1, 1989
[Risk-adapted therapy of highly malignant non-Hodgkin's lymphomas with COP-BLAM/IMVP-16: a prospective multicenter study]H H Gerhartz, W Wilmanns, G Brittinger, et al.
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|January 1, 1989
Risk factor adapted treatment of Hodgkin's lymphoma: strategies and perspectivesM Loeffler, M Pfreundschuh, U Rühl, et al.
Blood|October 15, 1993
Randomized, double-blind, placebo-controlled, phase III study of recombinant human granulocyte-macrophage colony-stimulating factor as adjunct to induction treatment of high-grade malignant non-Hodgkin's lymphomasH H Gerhartz, M Engelhard, P Meusers, et al.
Medizinische Klinik (Munich, Germany : 1983)|November 15, 1992
[Recurrence of Hodgkin's disease after advanced primary stages. German Hodgkin's Study Group]R Fuchs, M Löffler, M Pfreundschuh, et al.
Seminars in Oncology|December 1, 1994
Recombinant human granulocyte-macrophage colony-stimulating factor as adjunct to chemotherapy in aggressive non-Hodgkin's lymphomasH H Gerhartz, M Engelhard, G Brittinger, et al.
Infection|January 1, 1992
Treatment of myelodysplastic syndromes (MDS) and high leukaemic risk with low-dose cytosine arabinoside (LD-AraC) plus granulocyte-macrophage colony-stimulating factor (rh GM-CSF). The EORTC Leukaemia GroupH H Gerhartz, R Marcus, A Delmer, et al.
Pageof 12

Showing results (91-100 of 118) with videos related to

Sort By:
Pageof 12
Leukemia Research|February 1, 1993
Intervention treatment of established neutropenia with human recombinant granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in patients undergoing cancer chemotherapyH H Gerhartz, A C Stern, B Wolf-Hornung, et al.
Onkologie|February 1, 1988
[Multicenter prospective risk-adapted study on the therapy of non-Hodgkin's lymphomas of high malignancy. Use of COP-BLAM/IMVP-16 and randomized adjuvant radiotherapy--study concept and preliminary results]W Siegert, D Huhn, A Neubauer, et al.
Medical Oncology and Tumor Pharmacotherapy|January 1, 1989
Chemotherapy of Hodgkin's lymphoma with alternating cycles of COPP (cyclophosphamide, vincristin, procarbazine, prednisone) and ABVD (doxorubicin, bleomycin, vinblastine and dacarbazine). Results of the HD1 and HD3 trials of the German Hodgkin Study GroupV Diehl, M Pfreundschuh, M Löffler, et al.
Bone Marrow Transplantation|December 1, 1989
Low-dose Ara-C plus granulocyte/macrophage colony-stimulating factor for the treatment of myelodysplastic syndromes. EORTC Leukemia GroupH H Gerhartz, G Visani, A Delmer, et al.
Onkologie|February 1, 1989
[Risk-adapted therapy of highly malignant non-Hodgkin's lymphomas with COP-BLAM/IMVP-16: a prospective multicenter study]H H Gerhartz, W Wilmanns, G Brittinger, et al.
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|January 1, 1989
Risk factor adapted treatment of Hodgkin's lymphoma: strategies and perspectivesM Loeffler, M Pfreundschuh, U Rühl, et al.
Blood|October 15, 1993
Randomized, double-blind, placebo-controlled, phase III study of recombinant human granulocyte-macrophage colony-stimulating factor as adjunct to induction treatment of high-grade malignant non-Hodgkin's lymphomasH H Gerhartz, M Engelhard, P Meusers, et al.
Medizinische Klinik (Munich, Germany : 1983)|November 15, 1992
[Recurrence of Hodgkin's disease after advanced primary stages. German Hodgkin's Study Group]R Fuchs, M Löffler, M Pfreundschuh, et al.
Seminars in Oncology|December 1, 1994
Recombinant human granulocyte-macrophage colony-stimulating factor as adjunct to chemotherapy in aggressive non-Hodgkin's lymphomasH H Gerhartz, M Engelhard, G Brittinger, et al.
Infection|January 1, 1992
Treatment of myelodysplastic syndromes (MDS) and high leukaemic risk with low-dose cytosine arabinoside (LD-AraC) plus granulocyte-macrophage colony-stimulating factor (rh GM-CSF). The EORTC Leukaemia GroupH H Gerhartz, R Marcus, A Delmer, et al.
Pageof 12